ABSTRACT-In the present study, we reported that kinsenoside, a major component of Anoectochilus formosanus, inhibited inflammatory reactions in mouse peritoneal lavage macrophages and protects mice from endotoxin shock. In LPSstimulated mouse peritoneal lavage macrophages, kinsenoside inhibited the inflammatory mediators, such as nitric oxide, TNF-!, IL-1", monocyte chemoattractant protein 1, and macrophage migration inhibitory factor production. Furthermore, kinsenoside decreased the formation of a nuclear factor .BYDNA complex and nuclear p65 and p50 protein levels. Kinsenoside inhibited nuclear factor .B translocation through both I.B!-dependent and -independent pathway. In contrast, it stimulated anti-inflammatory cytokine IL-10 generation and enhanced the mRNA expression of IL-10 and suppressor of cytokine signaling 3 in the same cells induced by LPS. In an animal model, both pretreatment and posttreatment of kinsenoside increased the survival rate of ICR mice challenged by LPS (80 mg/kg, i.p.). Pretreatment with kinsenoside decreased serum levels of TNF-!, IL-1", IL-10, monocyte chemoattractant protein 1, and migration inhibitory factor at 1 h after sublethal dose of LPS (40 mg/kg, i.p.) in mice. In contrast, kinsenoside enhanced serum IL-10 level at 24 h after LPS injection in mice. In conclusion, kinsenoside inhibited the production of inflammatory mediators and enhanced antiinflammatory cytokine generation. Therefore, kinsenoside can alleviate acute inflammatory hazards.
INTRODUCTION
During the inflammatory process, macrophages play a central role in mediating various immunopathologic responses, including the production of inflammatory mediators and antiinflammatory cytokines (1) . Macrophages are activated by various mediators, including LPS, which is a constituent of the cell wall of gram-negative bacteria (1) . There are many regulators involved in the inflammation process, and the nuclear factor .B (NF-.B) signaling pathway seems to have a central function in the regulation of the inflammation (2) . In unstimulated cells, NF-.B is constitutively localized in the cytosol. After activation, including LPS stimuli, the NF-.B is translocated to the nucleus, where it activates the transcription of target genes, including genes encoding for proinflammatory cytokines, chemokines, iNOS, and anti-inflammatory cytokines (2) .
Kinsenoside [3-(R)-3-"-D-glucopyranosyloxybutanolide ( Fig. 1 ) is a significant and active compound of Anoectochilus formosanus (Orchidaceae), an important ethnomedicinal plant of Taiwan. A. formosanus is used as health food for liver disease in Taiwan and other Asian countries (3) . Currently, we have reported that a standardized aqueous extract of A. formosanus significantly reduces thioacetamide-induced hepatic fibrosis in mice, probably through inhibition of hepatic Kupffer cell activation (4) . In vitro study also showed that kinsenoside inhibited TNF-! secretion from Kupffer cells, hepatic macrophages, to LPS stimulation (4) . These results suggest that kinsenoside may protect the liver from thioacetamideinduced injury through inhibiting the activation of Kupffer cells, by suppressing inflammation. Therefore, in this study, we examined the anti-inflammatory properties of kinsenoside both in vitro and in vivo.
MATERIALS AND METHODS

Preparation of kinsenoside
The identity and purity of kinsenoside (985%) was analyzed by highpressure liquid chromatography according to the previous report (5) .
Animals
Male ICR mice were obtained from BioLASCO Co, Ltd (Taipei, Taiwan) and fed with a standard laboratory diet and tap water ad libitum. Experimental animals were housed in an air-conditioned room at 22-C to 25-C with a 12-h light-dark cycle. All animals received humane care, and the study protocols were in compliance with institutional guidelines of China Medical University for the use of laboratory animals.
Isolation of mouse peritoneal lavage macrophages
Mouse macrophages were isolated from the peritoneal cavity of 7-week-old mice, 3 days after the injection of 1 mL endotoxin-free 5% thioglycolate medium (BD Pharmingen, San Jose, Calif). Peritoneal fluid from mice were harvested from peritoneal cavities by infusing 5 mL ice-cold sterile Hanks buffered salt solution. After centrifugation at 300g for 5 min, the cell pellets were suspended in Dulbecco's modified Eagle medium (Hyclone, Logan, Utah) supplemented with 10% fetal bovine serum, penicillin 100 U/mL, and streptomycin 100 U/mL. The cells were plated onto 24-well (1 Â 10 6 cells) or 6-cm culture dish (1 Â 10 7 cells) for cytokine detection or RNA protein extract, respectively. Nonadherent cells were removed after 4-h culture.
For the experiments, cells cultured for 4 h were washed and cultured in fresh medium with various concentrations of kinsenoside (10, 25, and 50 2M) 184 SHOCK, Vol. 35, No. 2, pp. 184Y190, 2011
Nitrite and cytokines determinations
The production of NO was determined by measuring the accumulation of nitrite in culture medium based on the Griess reaction. Nitrite in the culture medium was determined by Griess reagent (Sigma, St Louis, Mo). Concentrations of cytokines, such as TNF-!, IL-1", IL-10, monocyte chemoattractant protein 1 (MCP-1) (eBioscience, San Diego, Calif), and macrophage migration inhibitory factor (MIF; R&D Systems, Minneapolis, Minn) in the supernatants of cell culture was determined using an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions.
Preparation of cytoplasmic and nuclear extracts and Western blot analysis
The cytoplasmic and nuclear protein extracts were described previously (6) . The mouse peritoneal lavage macrophages (MPLMs) were incubated with or without LPS in the presence or absence of kinsenoside. The cells (1.0 Â 10 7 ) were washed with ice-cold phosphate-buffered saline and suspended in 0.2 mL hypotonic lyses buffer (10 mM HEPES, pH 7.9; 10 mM KCl; 1 mM dithiothreitol [DTT]; 1 mM phenylmethysulfonyl fluoride; 1 mM sodium fluoride; 1 mM orthovanadate; 10 2M EGTA; 10 2M EDTA) containing 0.5% Nonidet P-40 and microcentrifuged at 12,000g for 1 min. The homogenate was centrifuged, and supernatant containing the cytoplasmic extracts was removed and stored frozen at j80-C. The nuclear pellet was lysed in 20 2L of ice-cold nuclear extraction buffer (20 mM HEPES, pH 7.9; 400 mM NaCl; 1 mM DTT; 1 mM phenylmethysulfonyl fluoride; 1 mM sodium fluoride; 1 mM orthovanadate; 10 2M EGTA; 10 2M EDTA) for 1 h of intermittent mixing; the extract was centrifuged. The lysates were centrifuged at 12,000g for 15 min at 4-C, and supernatants containing nuclear extracts were secured. The protein concentration was determined using the Bradford protein assay reagent (Sigma-Aldrich, St Louis, Mo) according to the manufacturer's instruction.
The MPLMs cytoplasmic and nuclear protein extracts (40 and 20 2g, respectively) were separated by 12% sodium dodecyl sulfateYpolyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. After blocking with 5% nonfat milk and then incubated overnight at 4-C with various primary antibodies in Tris-buffered saline containing 0.1% Tween-20. The primary antibodies were obtained from the following sources: anti-p65, antiphospho-p65 (anti-pp65), antiYphospho-I.B!, and anti-I.B! from Cell Signaling (Danvers, Mass) and antiYproliferating cell nuclear antigen, antiY!-tubulin, and anti-p50 from Santa Cruz Biotechnology (Santa Cruz, Calif ). Thereafter, the blot was washed, exposed to horseradish peroxidaseYconjugated secondary antibodies for 1 h, and then developed by enhanced chemiluminescence (Thermo, Rockford, Ill). Proliferating cell nuclear antigen and !-tubulin were used as an internal control in nuclear and cytoplasmic experiments, respectively.
Electrophoretic mobility shift assay
To determine NF-.B activation, the sequence of the NF-.BYbinding oligonucleotide used as a fluorescence DNA probe was cy5.5-5 ¶-AGCTTGGGG ACTTTCCGA-3 ¶ (Bio-protech, Taipei, Taiwan). The DNA-binding reaction was performed at room temperature in a volume of 20 2L, which contained the binding buffer (10 mM Tris-HCl, pH 7.5; 50 mM NaCl; 1 mM DTT), 1 2g of poly(dI-dC), 50 nM cy5.5-labeled probe, 0.5% Tween-20, and 15 2g of nuclear extracts. After incubation for 30 min, the samples were electrophoresed on native 5% acrylamide gels prepared in 0.5Â TBE buffer (Amresco, Solon, Ohio). Supershift assay using anti-p65 and anti-p50 antibody was also conducted to confirm the specificity of NF-.B DNA-binding activity. BCold[ represents nuclear extract preincubated with an excess of unlabeled oligonucleotide. Subsequently, the gel was transferred to and imaged on a LI-COR Odyssey infrared imaging system (LI COR Biosciences, Lincoln, Nebr) at 700-nm channels and 169-2m resolution. The density of fluorescence in each band was measured in triplicate with the use of the LI-COR imaging software.
RT-PCR analysis
Total RNA was isolated from the MPLMs cultured by the acid guanidinium thiocyanate-phenol-chloroform extract method, as described by Chomczynski and Sacchi (7) . A 3-2g sample of total RNA was subjected to reverse transcription with Moloney murine leukemia virus RT in a 50-2L reaction volume. Aliquots of the RT mix were used in amplification by PCR of fragments of IL-10 and suppressor of cytokine signaling 3 (SOCS-3) with the mice primer pairs listed in Table 1 . The expression levels of all the transcripts were normalized to that of GAPDH mRNA in the same tissue sample. Polymerase chain reaction product identities were confirmed by sequence analysis. The PCR products were separated on a 2% agarose gel and recorded on Polaroid film; the bands were quantified with a densitometer.
Survival rate after LPS-induced endotoxic shock
When the mice attained a weight of 24 to 26 g, they were used in the experiments. The mice were divided randomly into three groups, such as model, and two kinsenoside treatment groups, according to their body weight. In the prophylactic experiment, LPS (80 mg/kg) was administered by i.p. injection 1 h after kinsenoside (100, 300 mg/kg; i.p.) or saline treatment. The number of surviving mice was observed for 72 h. In the therapeutic experiment, kinsenoside (100, 300 mg/kg; i.p.) and saline were injected i.p. at 1 and 6 h after LPS (80 mg/kg, i.p.) administration. The number of surviving mice was observed for 72 h.
LPS-induced inflammatory model in mice
To examine the effect of kinsenoside on serum cytokines profile in acute inflammation, the sublethal dose of 40 mg/kg of LPS was used in this experiment. When the mice attained a weight of 24 to 26 g, 40 mice were randomly divided into four groups (containing 10Y12 mice per group), such as control, model, and two kinsenoside (100, 300 mg/kg; i.p.) treatment groups. Except for the control group, LPS was administered by i.p. injection 1 h after kinsenoside (100, 300 mg/kg; i.p.) treatment. The control group was given equal volume of saline to substitute LPS.
After 1 h of LPS treatment, blood was collected from the mice via the retroorbital sinus. At the end of the experiment (24 h after LPS injection), mice were killed under CO 2 anesthesia, and blood was withdrawn from the abdominal vein.
The concentrations of the sera TNF-!, IL-6, IL-10, MCP-1, and MIF were measured by ELISA using commercially available kits (eBioscience) according to the manufacturer's instructions.
Statistical analysis
Results are expressed as the mean (SD). All experimental data were analyzed by one-way ANOVA following the Dunnett test. The statistical significance of differences between groups of animals in survival experiments was analyzed by the Kaplan-Meier test. Difference with P G 0.05 was considered statistically significant.
RESULTS
Effect of kinsenoside on inflammatory mediator production in LPS-stimulated MPLMs
The culture treatment of MPLMs with 1 2g/mL LPS for 24 h caused a dramatic increase in IL-1", IL-10, TNF-!, NO, MCP-1, and MIF production (Fig. 2) . LPS induced the production of IL-1", TNF-!, NO, MCP-1, and MIF were inhibited by kinsenoside (10Y50 2M) pretreatment in a concentration-dependent manner. In contrast, the release of IL-10 was increased by kinsenoside (50 2M) pretreatment. Mouse peritoneal lavage macrophages did not undergo any change in viability after exposure to LPS + kinsenoside (data unpublished).
Effect of kinsenoside on protein expression of I.B!, pI.B!, pp65, p65, and p50 in LPS-stimulated MPLMs
Mouse peritoneal lavage macrophages were incubated with LPS in the presence or absence of kinsenoside for 30 min. Treatment with LPS for 30 min increased cytoplasmic protein expression levels of pI.B! and pp65, but not I.B!, by Western blot analysis (Fig. 3A) . The expression levels of pI.B! and pp65 in the LPS group were 145% and 123%, respectively, all of them greater than those in the control group (Fig. 3) . Kinsenoside treatment did not affect the expression of I.B!. Pretreatment of kinsenoside led to decreases of 45% (25 2M) and 63% (50 2M) of pI.B! expression and also 43% (25 2M) and 55% (50 2M) of pp65 expression (Fig. 3A) .
Mouse peritoneal lavage macrophages were incubated with LPS in the presence or absence of kinsenoside for 30 min. Treatment with LPS for 30 min caused translocations of p65 and p50 into nucleus by Western blotting. The expression levels of p65 and p50 in the LPS group were 126% and 151%, respectively, all of them greater than those in the control group (Fig. 3B) . Pretreatment of kinsenoside led to decreases of 25% (25 2M) and 31% (50 2M) of p65 expression and 18% (25 2M) and 37% (50 2M) of p50 expression (Fig. 3B) .
Effect of kinsenoside on LPS-induced NF-.B activation
The MPLMs were pretreated with kinsenoside for 30 min and then treated with LPS (1 2g/mL) for 30 min. LPS treatment caused a significant increase in the DNA-binding activity of NF-.B, as determined by electrophoretic mobility shift assay (EMSA) (Fig. 4A) . Pretreatment with kinsenoside (25 and 50 2M) significantly suppressed the induced DNA-binding activity of NF-.B by LPS. Supershift assay of NF-.BYDNA probe binding showed that LPS-activated NF-.B consisted of p50 and 65 subunits (Fig. 4B) .
Kinsenoside inhibited the mRNA expression of IL-10 and SOCS-3 in LPS-stimulated MPLMs
Fragments of IL-10 and SOCS-3 genes were amplified by RT-PCR (Fig. 5A) . The IL-10/GAPDH and SOCS-3/GAPDH ratios in the LPS group were 118% and 120%, respectively, all of them greater than those in the control group (Fig. 5B) . Pretreatment with kinsenoside (25, 50 2M) led to 18.9% and 24.5%, 22.2%, and 31.5% increase in IL-10/GAPDH and SOCS-3/GAPDH ratios, respectively.
Kinsenoside increased the survival rate after LPS-induced endotoxic shock
Mice received an i.p. injection of LPS (80 mg/kg). Six hours after LPS, mice clearly displayed the symptoms of endotoxic shock, such as decreased motor activities, ruffled fur, diarrhea, and ocular exudates. Figure 6A showed that 48 h after LPS, 90% of mice treated with saline died. In 48 h, 50% and 40% of mice treated with kinsenoside 100, 300 mg/kg died, respectively.
Because the studies described above suggested that kinsenoside prevents endotoxin shock, we next examined the therapeutic effects of kinsenoside. To investigate the therapeutic effects, kinsenoside were treated at 1 and 6 h after LPS injection. As shown in Figure 6B , 83.3% of the mice died within 24 h in the saline treatment. In 36 h, 70% and 50% of mice treated with kinsenoside 100, 300 mg/kg died, respectively.
Effect of kinsenoside on serum cytokine levels in LPS-induced endotoxic shock
To determine the effects of kinsenoside on inflammatory cytokines involved in the endotoxemia of LPS, serum levels of IL-1", IL-10, TNF-!, MCP-1, and MIF were determined by ELISA. Kinsenoside was administered to mice 1 h before LPS treatment, and each cytokine level was determined at 1 and 24 h after LPS injection. One hour after LPS injection, serum concentrations of IL-1", IL-10, TNF-!, MCP-1, and MIF increased 2.7-, 27-, 7.9-, 3.1-, and 9.3-fold in LPS-treated mice as compared with the control group (Fig. 7, AYC and Fig. 8, A and B) . Administration of kinsenoside (100, 300 mg/kg, i.p.) significantly inhibited the increase in serum concentrations of IL-1", IL-10, TNF-!, MCP-1, and MIF.
There were no significant differences in serous IL-1", TNF-!, and MCP-1 levels at 24 h between LPS-treated group and control group. The kinsenoside treatment did not affect the serum levels of IL-1", TNF-!, and MCP-1 (Fig. 7, D and F  and Fig. 8C ). Twenty-four hours after LPS injection, serum concentration of IL-10 and MIF increased 4.8-and 7.6-fold in LPS-treated mice as compared with the control group (Fig. 7E) . Kinsenoside (300 mg/kg, i.p.) inhibited the increase in serum concentrations of MCP-1. In contrast, administration of kinsenoside (100, 300 mg/kg, i.p.) led to 45% and 59% increase in serum concentration of IL-10.
DISCUSSION
For the first time, this study clearly demonstrated that mice treated with kinsenoside exhibited improved survival to endotoxic shock. The protective mechanisms may involve decreased production of inflammatory cytokines and increased secretion of anti-inflammatory mediators.
Bacterial LPS/endotoxin, a cell wall component of gramnegative bacteria, is a potent activator of mammalian cells, such as macrophages (1) . It has been demonstrated that LPS, after binding to receptors on macrophages, could induce this inflammatory cells to release free radical NO (8), various cytokines, including TNF-! and IL-1" and IL-10 (9Y11). In this study, MPLMs were pretreated with kinsenoside for 30 min, and then the cells were stimulated by LPS for 24 h. We found that kinsenoside significantly inhibited LPS-induced NO, TNF-!, and IL-1" secretions in MPLMs.
Downstream to LPS activation, the ubiquitous transcription factor NF-.B activates transcription of a wide variety of genes, including those coding for iNOS, TNF-!, and IL-1" (8, 12) . The result of EMSA study showed that kinsenoside inhibited the LPS-induced DNA-binding activity of p65 and p50. Western blot analysis of nuclear protein also showed that kinsenoside suppressed the nuclear translocation of p65 and p50 proteins. We clearly demonstrated that anti-inflammatory effects of kinsenoside may be exerted partly via inhibition of NF-.B signaling.
In unstimulated cells, NF-.B is present in the cytosol as a homodimer or heterodimer and, in particular, is linked to the inhibitory protein I.B. Nuclear factor .B signaling is generally considered to occur through either the classic or alternative pathway. In the classic pathway, NF-.B activation results from the phosphorylation, ubiquitination, and proteosome-mediated degradation of inhibitory I.B protein and then followed by the nuclear translocation and DNA binding of NF-.B (2). In the alternative I.B-independent pathway, direct phosphorylation of NF-.B subunit p65 also modulates NF-.B transcription activity (13) . In this study, our results showed that the expression levels of cytoplasmic pI.B! and pp65 were increased under LPS stimulation. Kinsenoside significantly inhibited the expression of pI.B! and pp65, which indicated that kinsenoside IL-10 is a potent anti-inflammatory cytokine that inhibits the synthesis of NO and proinflammatory cytokines in MPLMs (14) . In this study, the production and mRNA expression of IL-10 in macrophages stimulated by LPS were enhanced by kinsenoside. These results suggest that some of the antiinflammatory effects of kinsenoside may be partly mediated by the release of IL-10, which in turn inhibited the release of NO and proinflammatory cytokines.
It has been reported that LPS-induced transcriptional activation of IL-10 is mediated by NF-.B pathway in mouse macrophage (15) . In this study, kinsenoside inhibited NF-.B activation in MPLMs, but enhanced IL-10 release. This result indicated that kinsenoside could enhance IL-10 release but not through NF-.B pathway. Dong et al. (16) showed that enhanced SOCS-3 gene expression could promote IL-10 production in placental trophoblast cells. In the present study, LPS-induced mRNA expression levels of IL-10 and SOCS-3 in MPLMs were enhanced by kinsenoside treatment. Kinsenosideinduced SOCS-3 expression might contribute to the production of IL-10. In addition, SOCS proteins are a family of intracellular proteins that control cytokine signaling by suppressing cytokine transduction process (17) . It has been shown that SOCS-3 mediates the inhibitory effects of IL-10 on LPS-induced macrophage activation (18) . Kinsenoside-induced SOCS-3 expression might contribute to the production and anti-inflammatory actions of IL-10.
Bacterial LPS in the bloodstream induces overexpression of various inflammatory mediators and large amounts of inflammatory mediators produced in the body are thought to contribute to the LPS-induced symptoms of endotoxic shock and molarity (19) . Thus, survival rate in murine endotoxic shock has been used as an indicator of anti-inflammatory effect. In an animal model with lethal endotoxemia (LPS 80 mg/kg, i.p.), the pretreatment or posttreatment of kinsenoside increased the LPS-induced survival rate. These observation strongly supports the hypothesis that kinsenoside has anti-inflammatory activity, not only in vitro but also in vivo.
The current study used a sublethal dose of 40 mg/kg of LPS, which allows for examining the profile of cytokines not only at the early but also at the late stage of LPS-induced acute inflammation. In this study, kinsenoside treatment decreased serum TNF-! and IL-1" levels at 1 h after LPS challenge in mice. Because the serum levels of TNF-! and IL-1" at 24 h after LPS injection are very low, no effect of kinsenoside is observed. Kinsenoside-suppressed TNF-! release in vivo was stronger than that in vitro, which indicated that kinsenoside was involved in other mechanisms in vivo to inhibit proinflammatory cytokine secretion. Currently, Borovikova et al. (20) showed that the efferent vagus nerve inhibited the release of TNF-! and other proinflammatory cytokines and attenuated the development of endotoxin-induced shock in rodents. The possibility of how kinsenoside activates vagally mediated neural anti-inflammation in vivo is required further to be investigated.
Kinsenoside treatment decreased the serum IL-10 level at 1 h after LPS challenge in mice. In contrast, kinsenoside enhanced the serum IL-10 level at 24 h after LPS challenge. It is known that host response to injury is finely regulated by the formation of both proinflammatory and anti-inflammatory cytokines. Whereas proinflammatory cytokines, such as TNF-! and IL-1", stimulate the body's defense mechanism by promoting inflammatory reactions to fight inflammatory stimuli and restore homeostasis, anti-inflammatory cytokines such as IL-10 lower inflammatory responses and prevent defense mechanisms from causing damage by overshooting (21) .
In the early phase, the serum levels of TNF-! and IL-1" were lower in the kinsenoside-treated group; therefore, the serum level of IL-10 of kinsenoside-treated group was lower than the LPS-alone group. In the late stage, kinsenoside enhanced the serum IL-10 level. In vitro study also clearly demonstrated that kinsenoside stimulated IL-10 release from MPLMs. These results suggested that the increased survival rate of kinsenoside-treated mice with endotoxemia may partly mediate the increase in anti-inflammatory cytokines.
Both MIF and MCP-1 were produced in macrophages induced by LPS (22, 23) . In MPLMs cell culture system, kinsenoside inhibited MIF and MCP-1 secretion. In in vivo study, we found that both serum concentrations of MIF and MCP-1 were increased by LPS treatment. It has been shown that anti-MIF antibody and blocker of MCP-1 synthesis could increase survival rates in LPS-induced endotoxemia (24, 25) . Kinsenoside decreased the LPS-induced MIF and MCP-1, indicating that it protected mice from LPS-induced endotoxin shock, partly through inhibiting the production of MIF and MCP-1.
In conclusion, our results demonstrated the beneficial effects of kinsenoside on endotoxic shock in mice. Multiple mechanisms were involved in the anti-inflammatory action of kinsenoside. Firstly, kinsenoside inhibited proinflammatory cytokine release via NF-.B pathway. Secondarily, kinsenosideenhanced anti-inflammatory cytokine release might be mediated through activation of SOCS-3. Finally, kinsenoside reduced the MIF and MCP-1 productions.
